| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_78941ed5a01bfbcd48376e1fdb485b19 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-042
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-044
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-347
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-04 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-689
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-435 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-435 |
| filingDate |
2017-06-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7310454de44be8e4edcdbbabede5503d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_599a15c0ed6f5f9a2fc374fff3dbb96d |
| publicationDate |
2019-03-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20190020693-A |
| titleOfInvention |
MENTSH analogs as therapeutic agents for diabetes, obesity, and related diseases and complications |
| abstract |
This application describes a new open reading frame that is mitochondria encoded, which results in the generation of new mitochondrial peptides. The specific small nucleotide polymorphism located within the ND-2 subunits interferes with the expression of these mitochondrial peptides, which is particularly correlated with increased obesity and diabetes in certain ethnic populations. In vitro administration of peptides increases insulin secretion, decreases fat accumulation and improves glucose uptake in muscle cells. In addition to SNP detection, antibodies generated against these peptides can also be used for peptide deprivation detection to aid in diagnostic methods. In vivo studies have also shown that administration of the peptide improves glucose tolerance, provides a new therapeutic pathway for new diabetes therapies, and reduces weight to function as a new obesity therapy. The production of synthetic analogues further enhances or eliminates activity over natural peptides. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11124551-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11760783-B2 |
| priorityDate |
2016-06-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |